Day: May 28, 2024

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead Compound PH-762

Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May...

error: Content is protected !!